Drugs / CBP-1019
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06576037 | Oct 2024 → Jun 2027 expected | neoplasm | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05830097 | Mar 2023 → Jun 2025 | breast cancer, colorectal cancer, esophageal cancer, lung cancer +1 | Coherent Biopharma (Hefei) Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CBP-1019 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05830097 ↗ |
| Modality | Other / unclassified | “CBP-1019, a bi-specific ligand conjugated drugs in patients with advanced solid tumors.” NCT05830097 ↗ |
| Route | Intravenous | “receive CBP-1019 IV infusion every 2 weeks” NCT05830097 ↗ |